Investigating how a specific therapy affects immune cells in inflammatory bowel disease.
Official title: DCs as clinical targets of anti-integrin therapy in IBD
Funded at Benaroya Research Inst at Virginia Mason · NIH-10993147 · Data updated 2026-11-12
This study is looking at how a treatment called vedolizumab helps people with inflammatory bowel disease (like Crohn's disease and ulcerative colitis) by examining certain immune cells in their blood and colon, with the goal of figuring out who might benefit the most from this therapy and finding better ways to manage their condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Benaroya Research Inst at Virginia Mason NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | December 1, 2023 |
| Project end | October 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $210,126 |
| NIH project number | 5R21AI176365-02 |
| Project ID | NIH-10993147 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with inflammatory bowel disease who are currently receiving or considering treatment with vedolizumab.
✕Less likely to help
Patients who do not have inflammatory bowel disease or those who are not eligible for vedolizumab therapy may not benefit from this research.
What this research studies
This research focuses on understanding how the anti-integrin therapy vedolizumab works in patients with inflammatory bowel disease (IBD), which includes conditions like Crohn's disease and ulcerative colitis. The researchers aim to analyze dendritic cells from the blood and colon of IBD patients to see how these cells respond to the therapy and how this relates to inflammation. By observing these immune cells, the study hopes to improve predictions about who will benefit from the treatment and to develop new strategies for managing IBD.
Why it matters
Potential benefit: If successful, this research could lead to better treatment options and improved outcomes for patients with inflammatory bowel disease.
How similar studies have gone: Previous research has shown promising results with anti-integrin therapies in IBD, but this specific focus on dendritic cells is a novel approach.
Where this research is happening
-
Benaroya Research Inst at Virginia Mason
Seattle, United States Active
Researchers
- Principal investigator: Lord, James Daniel — Benaroya Research Inst at Virginia Mason
- Study coordinator: Lord, James Daniel
Related research
Other NIH-funded projects on the same topics.
-
T cells and the switch from pre-autoimmunity to autoimmune disease
A study following people at risk for type 1 diabetes and people with Down syndrome to understand how certain T cells may shift toward causing autoimmune disease.
-
Genetic and epigenetic control of T cell function in autoimmune disease
This grant aims to understand how genetic and epigenetic changes affect how T cells behave in autoimmune diseases to find ways to reduce harmful immune responses.
-
Immune Tolerance Network (ITN) for immune tolerance therapies across autoimmune and allergic diseases
A national network runs clinical trials to test new immune-tolerance therapies that could help people with autoimmune and allergic diseases.
-
Immune Tolerance Network for safer, more effective immune therapies
A nationwide network tests new immune therapies to help people with autoimmune diseases, allergies, and transplant patients reach better control of their immune system.
-
Immune tolerance research network for safer transplant and autoimmune therapies
A national effort tests new treatments that make the immune system tolerate transplanted organs and fight autoimmune and allergic diseases more safely.
-
Immune Tolerance Network for allergy, autoimmunity, and transplantation
A large NIH program tests new immune-tolerance therapies to help people with autoimmune diseases, allergies, and transplant patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.